What is the latest GKB stock price?
The latest stored price for GKB is Rs 60.28 as of 2026-10-09.
gimli
GKB stock AI analysis
GKB Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
GKB OPHTHALMICS LTD. is a small-cap stock in Healthcare. This Gimli page shows the latest available GKB price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹60.28
1W return
-6.34%
1M return
-9.26%
3M return
n/a
6M return
n/a
1Y return
n/a
Market cap
₹n/a
PE
n/a
PB
n/a
ROE
+2.17%
ROCE
+8.39%
RSI
39.26
Turnover
₹0.01 cr
Why it can matter in screens
- Momentum: GKB is below 50DMA, below 200DMA; RSI is 39.26.
- Returns: 1D -4.18%, 1W -6.34%, 1M -9.26%, 3M n/a, 1Y n/a.
- Trend levels: 52W high ₹76.02, 52W low ₹58.25, off high -20.71%.
- Liquidity: latest turnover is ₹0.01 cr; volume vs 20D is +0.28%.
- Valuation/profitability: PE n/a, PB n/a, ROE +2.17%, ROCE +8.39%.
- Growth: 3Y sales CAGR +25.51%, 3Y profit CAGR n/a.
Quick Answers
Is GKB above its 50DMA and 200DMA?
GKB is below 50DMA, below 200DMA. The latest 50DMA is n/a and the latest 200DMA is n/a.
What are GKB PE, ROE and ROCE?
GKB has PE n/a, ROE +2.17%, and ROCE +8.39% in Gimli's latest available snapshot.
How has GKB performed recently?
GKB has returned -9.26% over 1 month, n/a over 3 months, and n/a over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 29.79 cr | 2.39 cr | 0.19 cr | n/a |
| 2025-12-31 | 56.79 cr | 2.23 cr | 0.44 cr | n/a |
| 2025-09-30 | 30.17 cr | 3.39 cr | 1.60 cr | n/a |
| 2025-06-30 | 32.31 cr | 1.00 cr | -1.02 cr | n/a |
| 2025-03-31 | 31.02 cr | -2.50 cr | -3.55 cr | n/a |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 149.06 cr | 8.17 cr | 1.22 cr | 2.42 |
| 2025-03-31 | 108.99 cr | -2.07 cr | -7.04 cr | nan |
| 2024-03-31 | 88.25 cr | 1.51 cr | -2.81 cr | nan |
| 2023-03-31 | 75.38 cr | 4.26 cr | -0.17 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 132.17 cr | 2.67 cr | 11.66 cr | 54.89 cr |
| 2025-03-31 | 125.21 cr | 3.02 cr | 14.50 cr | 56.44 cr |
| 2024-03-31 | 114.50 cr | 3.23 cr | 11.49 cr | 64.20 cr |
| 2023-03-31 | 112.09 cr | 2.36 cr | 11.22 cr | 67.30 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | -3.81 cr | -4.83 cr | n/a |
| 2025-03-31 | -3.43 cr | -5.58 cr | n/a |
| 2024-03-31 | 4.22 cr | 2.14 cr | n/a |
| 2023-03-31 | -2.77 cr | -3.99 cr | n/a |
Shareholding Trend
No recent data available.
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 422,282.96 cr | 34.857273 | +15.50% | +6.12% |
| DIVISLAB | DIVI S LABORATORIES LTD | 247,947.67 cr | 85.088426 | +18.37% | +52.32% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,610.64 cr | 72.265309 | +17.33% | +31.16% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 115,423.17 cr | 58.937484 | +21.03% | +4.32% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,446.65 cr | 25.058308 | +16.04% | +12.37% |
| LAURUSLABS | LAURUS LABS LIMITED | 109,947.20 cr | 100.670416 | +21.77% | +135.42% |
| CIPLA | CIPLA LTD | 105,094.85 cr | 31.162389 | +10.25% | -14.02% |
| DRREDDY | DR. REDDY S LABORATORIES | 99,661.60 cr | 30.096514 | +9.23% | -3.94% |
Try these prompts
- Analyze GKB OPHTHALMICS. with valuation, momentum and industry peers
- Compare GKB with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare GKB with other Healthcare stocks
Data snapshot: 2026-10-09. Not investment advice.